Achieving deep responses in previously treated CLL patients

Danielle Brander

Danielle Brander, MD from Duke University School of Medicine, Durham, NC discusses the latest updates from the Phase Ib clinical trial, NCT01682616, investigating the combination of venetoclax and rituximab in chronic lymphocytic leukemia (CLL) patients who have previously received treatment. This trial looked specifically at the safety of the combination therapy and at markers of efficacy. At the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2017 held in New York, NY, Dr Brander presented data on patients who had a deep response to the treatment and could thus stop treatment.

Share this video